POLE/POLD1 mutation and tumor immunotherapy

被引:62
|
作者
Ma, Xiaoting [1 ]
Dong, Lin [2 ]
Liu, Xiu [1 ]
Ou, Kai [1 ]
Yang, Lin [1 ]
机构
[1] Chinese Acad Med Sci & Peking Union Med Coll, Natl Canc Ctr, Dept Med Oncol, Natl Clin Res Ctr Canc,Canc Hosp, Beijing 100021, Peoples R China
[2] Chinese Acad Med Sci & Peking Union Med Coll, Natl Canc Ctr, Dept Pathol, Natl Clin Res Ctr Canc,Canc Hosp, Beijing 100021, Peoples R China
关键词
Immune checkpoint inhibitor; MSI; POLD1; POLE; Tumor; Tumor mutation burden; DNA-POLYMERASE EPSILON; COLORECTAL-CANCER; GERMLINE MUTATIONS; DOMAIN MUTATIONS; IMMUNE-RESPONSE; HUMAN COLON; POLE; SAFETY; PD-1; PEMBROLIZUMAB;
D O I
10.1186/s13046-022-02422-1
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
POLE and POLD1 encode the catalytic and proofreading subunits of DNA polymerase epsilon and polymerase delta, and play important roles in DNA replication and proofreading. POLE/POLD1 exonuclease domain mutations lead to loss of proofreading function, which causes the accumulation of mutant genes in cells. POLE/POLD1 mutations are not only closely related to tumor formation, but are also a potential molecular marker for predicting the efficacy of immunotherapy in pan-carcinomatous species. The association of POLE/POLD1 mutation, ultra-high mutation load, and good prognosis have recently become the focus of clinical research. This article reviews the function of POLE/POLD1, its relationship with deficient mismatch repair/high microsatellite instability, and the role of POLE/POLD1 mutation in the occurrence and development of various tumors.
引用
收藏
页数:10
相关论文
共 50 条
  • [1] POLE/POLD1 mutation and tumor immunotherapy
    Xiaoting Ma
    Lin Dong
    Xiu Liu
    Kai Ou
    Lin Yang
    Journal of Experimental & Clinical Cancer Research, 41
  • [2] Analysis of mutation detection of POLD1/pole in pan-cancer.
    Yang, Gao
    Huang, Jian'An
    Zu, Yukun
    Zhang, Yan
    Dai, Pingping
    Han, Yaqian
    Geng, Guojun
    Zhu, Xiaolei
    Chang, Ruimin
    Huan, Jiaojiao
    Chen, Chen
    Guan, Yan-Fang
    Yang, Ling
    Yi, Xin
    Xia, Xuefeng
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [3] Assessment of POLE and POLD1 mutations as prognosis and immunotherapy biomarkers for stomach adenocarcinoma
    Zhu, Mingyu
    Cui, Haiyan
    Zhang, Lu
    Zhao, Kuo
    Jia, Xiaochen
    Jin, Hao
    TRANSLATIONAL CANCER RESEARCH, 2022, 11 (01) : 193 - 205
  • [4] Comprehensive analysis of POLE and POLD1 mutation in 9322 Chinese cancer patients
    Dong, Hua
    Bai, Yuezong
    Cao, Xinkai
    Wang, Yanyan
    Shi, Lin
    Li, Fugen
    Ye, Yizhou
    Sun, Shuyang
    CANCER RESEARCH, 2019, 79 (13)
  • [5] Germinal mutations in POLE and POLD1 genes
    Machackova, Eva
    Vasickova, Petra
    Hazova, Jana
    Misove, Adela
    Foretova, Lenka
    EUROPEAN JOURNAL OF HUMAN GENETICS, 2023, 31 : 249 - 250
  • [6] The landscape of POLE/POLD1 mutations in Chinese solid tumor patients.
    Pang, Linrong
    Xu, Tao
    Tao, Hua
    Chen, Gang
    Ni, Bin
    Zeng, Daobing
    Wang, Aodi
    Shi, Weiwei
    Wang, Kai
    Yao, Ming
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [7] POLE and POLD1 germline variants in familial glioma
    Weber, Christine A. M.
    Brand, Frank
    Foerster, Alisa
    Geffers, Robert
    Auber, Bernd
    Samii, Amir
    Krauss, Joachim K.
    Wiese, Bettina
    Hartmann, Christian
    Weber, Ruthild G.
    EUROPEAN JOURNAL OF HUMAN GENETICS, 2023, 31 : 527 - 527
  • [8] Risk of colorectal cancer for carriers of a germ-line mutation in POLE or POLD1
    Buchanan, Daniel D.
    Stewart, Jenna R.
    Clendenning, Mark
    Rosty, Christophe
    Mahmood, Khalid
    Pope, Bernard J.
    Jenkins, Mark A.
    Hopper, John L.
    Southey, Melissa C.
    Macrae, Finlay A.
    Winship, Ingrid M.
    Win, Aung Ko
    GENETICS IN MEDICINE, 2018, 20 (08) : 890 - 895
  • [9] Evaluation of POLE and POLD1 Mutations as Biomarkers for Immunotherapy Outcomes Across Multiple Cancer Types
    Wang, Feng
    Zhao, Qi
    Wang, Ying-Nan
    Jin, Ying
    He, Ming-Ming
    Liu, Ze-Xian
    Xu, Rui-Hua
    JAMA ONCOLOGY, 2019, 5 (10) : 1504 - 1506
  • [10] Germline mutations in POLE and POLD1 associated with hereditary cancer
    Mur, P.
    Garcia Mulero, S.
    del Valle, J.
    Vidal, A.
    Pineda, M.
    Cinnirella, G.
    Martin-Ramos, E.
    Lopez-Doriga, A.
    Belhadj, S.
    Munoz-Torres, P. M.
    Navarro, M.
    Balmana, J.
    Brunet, J.
    Moreno, V.
    Piulats, J.
    Matias-Guiu, X.
    Sanz-Pamplona, R.
    Aligue, R.
    Capella, G.
    Lazaro, C.
    Valle, L.
    EUROPEAN JOURNAL OF HUMAN GENETICS, 2019, 27 : 1571 - 1571